Related Experiment Videos

Clinical utility in maximizing CD34+ cell count in stem cell grafts

¹Allogeneic Transplantation, Northwestern University, Chicago, Illinois 60612, USA.

Stem Cells (Dayton, Ohio)

|December 22, 1999

Abstract:

Many different stem cell subsets have been identified. Some of these subsets are multipotent, able to develop into any one of several cell types, while other stem cell subsets are committed to differentiated myeloid, lymphoid, erythroid, or megakaryocytic lineages.

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Autologous haematopoietic stem cell transplantation as a first-line disease-modifying therapy in patients with 'aggressive' multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2021

Cardiopulmonary assessment of patients with systemic sclerosis for hematopoietic stem cell transplantation: recommendations from the European Society for Blood and Marrow Transplantation Autoimmune Diseases Working Party and collaborating partners.

Bone marrow transplantation·2017

Brazilian experience with two conditioning regimens in patients with multiple sclerosis: BEAM/horse ATG and CY/rabbit ATG.

Bone marrow transplantation·2009

T-cell clones persisting in the circulation after autologous hematopoietic SCT are undetectable in the peripheral CD34+ selected graft.

Bone marrow transplantation·2009

Autologous peripheral blood CD133+ cell implantation for limb salvage in patients with critical limb ischemia.

Bone marrow transplantation·2009

Autologous non-myeloablative haematopoietic stem cell transplantation for refractory systemic vasculitis.

Annals of the rheumatic diseases·2007

See all related articles